Optipharm.CO.LTD (KQ:153710) — Stock Price
Optipharm.CO.LTD (KQ:153710) is currently trading at ₩4800.00 KRW, up 0.73% today. Over the past 52 weeks, shares have ranged between ₩4260.00 and ₩6200.00. This page tracks Optipharm.CO.LTD's live share price on the KQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Optipharm.CO.LTD stock valuation.
Optipharm.CO.LTD (153710) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Optipharm.CO.LTD's daily closing share price and trading volume on the KQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Optipharm.CO.LTD Income Statement — Revenue, Profit & Earnings by Year
Optipharm.CO.LTD's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | ₩22.34 Billion | ₩19.64 Billion | ₩17.37 Billion | ₩16.01 Billion | ₩14.26 Billion |
| Cost of Revenue | ₩16.76 Billion | ₩14.74 Billion | ₩13.18 Billion | ₩12.29 Billion | ₩10.52 Billion |
| Gross Profit | ₩5.59 Billion | ₩4.90 Billion | ₩4.20 Billion | ₩3.72 Billion | ₩3.74 Billion |
| Research & Development | ₩2.82 Billion | ₩2.80 Billion | ₩2.95 Billion | ₩3.82 Billion | ₩5.02 Billion |
| SG&A | ₩1.57 Billion | ₩4.14 Billion | ₩3.49 Billion | ₩2.91 Billion | ₩2.85 Billion |
| Total Operating Expenses | ₩24.76 Billion | ₩22.09 Billion | ₩20.00 Billion | ₩19.39 Billion | ₩18.76 Billion |
| Operating Income | ₩-2.41 Billion | ₩-2.45 Billion | ₩-2.63 Billion | ₩-3.38 Billion | ₩-4.50 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | ₩504.07 Million | ₩544.33 Million | ₩477.34 Million | ₩353.51 Million | ₩173.78 Million |
| Income Before Tax | ₩-2.50 Billion | ₩-2.36 Billion | ₩-2.44 Billion | ₩-2.04 Billion | ₩-3.08 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | ₩-2.50 Billion | ₩-2.36 Billion | ₩-2.44 Billion | ₩-2.04 Billion | ₩-3.08 Billion |
Optipharm.CO.LTD Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Optipharm.CO.LTD's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | ₩40.77 Billion | ₩43.32 Billion | ₩39.28 Billion | ₩41.18 Billion | ₩41.17 Billion |
| Total Current Assets | ₩15.24 Billion | ₩18.67 Billion | ₩20.48 Billion | ₩21.55 Billion | ₩25.87 Billion |
| Cash & Equivalents | — | ₩10.40 Billion | ₩14.00 Billion | ₩15.52 Billion | ₩20.51 Billion |
| Short-term Investments | ₩7.60 Billion | ₩10.61 Billion | ₩13.40 Billion | ₩11.05 Billion | ₩13.92 Billion |
| Net Receivables | ₩1.44 Billion | ₩1.20 Billion | ₩1.37 Billion | ₩1.12 Billion | ₩1.00 Billion |
| Inventory | ₩2.37 Billion | ₩1.98 Billion | ₩2.11 Billion | ₩1.91 Billion | ₩1.46 Billion |
| Property, Plant & Equipment | — | ₩23.79 Billion | ₩18.32 Billion | ₩17.72 Billion | ₩13.61 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ₩15.37 Billion | ₩15.98 Billion | ₩14.13 Billion | ₩12.17 Billion | ₩10.21 Billion |
| Total Current Liabilities | ₩12.63 Billion | ₩12.73 Billion | ₩11.60 Billion | ₩9.26 Billion | ₩7.85 Billion |
| Long-term Debt | — | — | — | — | — |
| Net Debt | ₩8.03 Billion | ₩7.13 Billion | ₩7.36 Billion | ₩1.90 Billion | — |
| Total Stockholder Equity | ₩25.40 Billion | ₩27.34 Billion | ₩25.14 Billion | ₩29.01 Billion | ₩30.96 Billion |
| Retained Earnings | ₩-30.42 Billion | ₩-27.84 Billion | ₩-25.30 Billion | ₩-22.40 Billion | ₩-20.24 Billion |
Optipharm.CO.LTD Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Optipharm.CO.LTD generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩-1.55 Billion | ₩-595.50 Million | ₩-1.72 Billion | ₩-2.43 Billion | ₩-1.97 Billion |
| Capital Expenditures | ₩2.54 Billion | ₩1.74 Billion | ₩1.74 Billion | ₩4.60 Billion | ₩757.44 Million |
| Free Cash Flow | ₩-4.10 Billion | ₩-2.33 Billion | ₩-3.46 Billion | ₩-7.04 Billion | ₩-2.73 Billion |
| Investing Cash Flow | — | ₩1.02 Billion | ₩-3.59 Billion | ₩-1.94 Billion | ₩-7.39 Billion |
| Financing Cash Flow | — | ₩942.99 Million | ₩1.99 Billion | ₩1.76 Billion | ₩1.82 Billion |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | ₩704.80 Million | ₩587.33 Million | — | ₩-33.61 Million | ₩-5.90 Million |
| Depreciation | ₩1.67 Billion | ₩1.57 Billion | ₩1.39 Billion | ₩1.08 Billion | ₩1.04 Billion |
| Change in Cash | ₩-1.34 Billion | ₩1.37 Billion | ₩-3.32 Billion | ₩-2.61 Billion | ₩-7.54 Billion |
Optipharm.CO.LTD Earnings History — EPS Actual vs. Analyst Estimates
Track Optipharm.CO.LTD's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 31, 2025 | -23.40 | — | — |
| Sep 30, 2025 | -37.30 | — | — |
| Jun 30, 2025 | -32.06 | — | — |
| Mar 31, 2025 | -77.60 | — | — |
| Dec 31, 2024 | -15.62 | — | — |
| Sep 30, 2024 | -35.88 | — | — |
| Jun 30, 2024 | -52.45 | — | — |
| Mar 31, 2024 | -56.69 | — | — |